InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,040.04
(
1.10%
)
US TECH 100
21,102.80
(
-0.45%
)
Dow Jones
43,297.03
(
0.91%
)
Brent Oil
73.57
(
0.38%
)
Bitcoin
95,597.99
(
-3.73%
)
Post# of 254016
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120928
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 187166

Thursday, 03/19/2015 7:47:19 PM

Thursday, March 19, 2015 7:47:19 PM

Post# of 254016
MRK starts phase-1 trial of new HCV drug for non-GT1 patients only:

https://clinicaltrials.gov/ct2/show/NCT02392494

At the least, the emergence of this new drug suggests that MRK’s other drugs—including the nuke from IDIX—do not comprise a satisfactory pan-genotypic regimen.

H/t @lomu_j.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up